English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Epilepsy is one of the most common and serious neurological conditions, affecting more than 50 million people worldwide. The current clinically available antiepileptic drugs are associated with a variety of side-effects and chronic toxicity. Adverse effects associated with these agents are the main limitation for their long-term use. Therefore, the development of new antiepileptic agent with improved efficacy and minimal adverse effects is very important. Trimetazidine (TMZ) is a lipophilic piperazine derivative, a drug of interest in ischemic diseases. It has demonstrated anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties in various experimental animal models. The aim of this study was to investigate the antioxidant effect of trimetazidine on pilocarpine-induced seizures in mice. Methods: Male Swiss mice, 25-30g received TMZ (5, 10 and 20 mg/kg, i.p.), fenobarbital (FEN 10 and 30 mg/Kg, i.p.), association (TMZ 5 + FEN 10 mg/kg, i.p.) or saline NaCl 0,9%, i.p. during seven days. 60 minutes after the last injection, pilocarpine (P320 mg/Kg, s.c.) was administered and behavioral tests were performed. After behavioral tests, animals were euthanized and cerebral areas were removed for neurochemical analysis. Results: Our results showed that TMZ administration reduced the number of deaths at all doses tested, but the highest dose (20 mg / kg) showed better effect, increased the latency of seizures in 41% (11.76 ± 0.75) compared to control ( 8.36 ± 0.41) led to absence seizures in 10% of animals and reduced the occurrence of status epilepticus. We observed an increase (168%) in glutamate levels in the hippocampus of animals that received pilocarpine and this effect was reversed with TMZ pretreatment at the higher dose. Conclusion: The results of this study suggest that trimetazidine presented anticonvulsant activity in the model of pilocarpine-induced seizures in mice, possibly due to its modulatory action on glutamatergic system.

SCNS. 12. Effects of trimetazidine on pilocarpine-induced convulsions in mice: behavioral changes and glutamatergic system modulation